These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 26452188)

  • 1. The time for molecular phenotyping of metastatic castrate-resistant prostate cancer is now.
    VanderWeele DJ
    Clin Adv Hematol Oncol; 2015 Sep; 13(9):580-3. PubMed ID: 26452188
    [No Abstract]   [Full Text] [Related]  

  • 2. There is no current role for molecular phenotyping in metastatic castrate-resistant prostate cancer.
    Vogelzang NJ
    Clin Adv Hematol Oncol; 2015 Sep; 13(9):580-5. PubMed ID: 26452189
    [No Abstract]   [Full Text] [Related]  

  • 3. Prognostic and predictive biomarkers in metastatic castration-resistant prostate cancer.
    Armstrong AJ
    Clin Adv Hematol Oncol; 2017 Mar; 15(3):184-188. PubMed ID: 28398272
    [No Abstract]   [Full Text] [Related]  

  • 4. Advances in systemic therapies for metastatic castration-resistant prostate cancer.
    Pant MK; Abughaban A; Aragon-Ching JB
    Future Oncol; 2014 Nov; 10(14):2213-26. PubMed ID: 25471035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarkers in castration-resistant prostate cancer.
    Armstrong AJ
    Clin Adv Hematol Oncol; 2014 Feb; 12(2):115-8. PubMed ID: 24892256
    [No Abstract]   [Full Text] [Related]  

  • 6. PARP inhibition in castration-resistant prostate cancer.
    Nappi L; Gleave ME
    Future Oncol; 2016 Mar; 12(5):577-80. PubMed ID: 26792387
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical phenotypes of castration-resistant prostate cancer.
    Zhang T; Armstrong AJ
    Clin Adv Hematol Oncol; 2013 Nov; 11(11):707-18. PubMed ID: 24896544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular landscape of prostate cancer: implications for current clinical trials.
    Khemlina G; Ikeda S; Kurzrock R
    Cancer Treat Rev; 2015 Nov; 41(9):761-6. PubMed ID: 26210103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Molecular biology of castration-resistant prostate cancer].
    Doucet L; Terrisse S; Gauthier H; Pouessel D; Le Maignan C; Teixeira L; Culine S
    Bull Cancer; 2015 Jun; 102(6):497-500. PubMed ID: 26028493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health-related quality of life in men with metastatic castration-resistant prostate cancer.
    Gee A; Challapalli A; Bahl A
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(6):941-9. PubMed ID: 26512743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Evolving Biology of Castration-Resistant Prostate Cancer: Review of Recommendations From the Prostate Cancer Clinical Trials Working Group 3.
    Geethakumari PR; Cookson MS; Kelly WK;
    Oncology (Williston Park); 2016 Feb; 30(2):187-95, 199. PubMed ID: 26888794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Antisense oligodeoxynucleotide therapy for castration-resistant prostate cancer].
    Miyake H; Fujisawa M
    Nihon Rinsho; 2014 Dec; 72(12):2121-5. PubMed ID: 25518344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of microRNA in castration-resistant prostate cancer.
    Thieu W; Tilki D; de Vere White R; Evans CP
    Urol Oncol; 2014 Jul; 32(5):517-523. PubMed ID: 24935732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of tumor tissue-derived DNA methylation biomarkers for the detection and therapy response evaluation of metastatic castration resistant prostate cancer in liquid biopsies.
    Dillinger T; Sheibani-Tezerji R; Pulverer W; Stelzer I; Hassler MR; Scheibelreiter J; Pérez Malla CU; Kuroll M; Domazet S; Redl E; Ely S; Brezina S; Tiefenbacher A; Rebhan K; Hübner N; Grubmüller B; Mitterhauser M; Hacker M; Weinhaeusel A; Simon J; Zeitlinger M; Gsur A; Kramer G; Shariat SF; Kenner L; Egger G
    Mol Cancer; 2022 Jan; 21(1):7. PubMed ID: 34980142
    [No Abstract]   [Full Text] [Related]  

  • 15. Current management of advanced and castration resistant prostate cancer.
    Gomella LG; Petrylak DP; Shayegan B
    Can J Urol; 2014 Apr; 21(2 Supp 1):1-6. PubMed ID: 24775717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Evaluation and diagnosis for castration resistant prostate cancer: CRPC].
    Kamoto T
    Nihon Rinsho; 2014 Dec; 72(12):2103-7. PubMed ID: 25518341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular alterations and emerging targets in castration resistant prostate cancer.
    Lorente D; De Bono JS
    Eur J Cancer; 2014 Mar; 50(4):753-64. PubMed ID: 24418724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment Sequencing in Metastatic Castration-Resistant Prostate Cancer: A Clinical Commentary.
    Stein CA
    Clin Genitourin Cancer; 2015 Oct; 13(5):407-9. PubMed ID: 26119230
    [No Abstract]   [Full Text] [Related]  

  • 19. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
    Shafi AA; Yen AE; Weigel NL
    Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is metastatic prostate cancer changing, and how will we know it? It's time for standard nomenclature for nonosseous metastases in clinical trials of patients with metastatic castration resistant prostate cancer.
    Tsao CK; Galsky MD; Oh WK
    Eur Urol; 2014 Aug; 66(2):184-5. PubMed ID: 24433812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.